Miami, FL – June 12, 2012 – Several groundbreaking studies on the Naviscan PET scanner, the breast
application for which is Positron Emission Mammography (PEM), were presented this week at the Annual Meeting
of the Society of Nuclear Medicine (SNM) in Miami, Florida. Researchers from the Johns Hopkins University,
Thomas Jefferson University, Boston University and University of Washington presented abstracts focusing on
use of novel radiotracers, new clinical applications as well as low-dose imaging with PEM.
Dr. Mathew Thakur from Thomas Jefferson University presented results of an ongoing head-to-head comparison
of 18 F-FDG with a novel low-dose radiotracer Cu-64-TP3805 (NuView Life Sciences, Park City, UT) demonstrating
concordance. This is significant since the dose from Cu-64 is similar to one mammogram and does not require
fasting indicating a potential for PEM to be used in a screening capacity. Dr. Richard Wahl of Johns Hopkins
University presented results on feasibility of using the technology for metabolic assessment and evaluation of
treatment response for patients with osteoarthritis. Drs Gustavo Mercier from Boston University and Lawrence
MacDonald from University of Washington shared clinical and research validations of performing PEM imaging
using 50% less radiation.
“The future of diagnostic imaging will be dependent on the optimization of molecular imaging technologies and
novel, targeted radiotracers,” stated Paul Mirabella, Chairman and CEO of Naviscan. “The goal is of this research
is to minimize dose without compromising the best possible diagnostic information. The ground breaking work of
these world renowned researchers is a significant step forward in the quest for such optimization.”
PEM imaging shows the location as well as the metabolic phase of a lesion. This information is critical in
determining whether a lesion is malignant and influences the course of treatment by providing an ability to
distinguish between benign and malignant lesions, what researchers term “specificity.” Recent studies have
demonstrated that PEM has similar sensitivity and higher specificity than breast MRI. The scanner is the only
FDA-cleared, CE-certified 3D Molecular Breast Imaging (MBI), device on the market with biopsy-guidance.
About Naviscan, Inc.
Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide
organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is
currently installed and available in breast and imaging centers throughout the world with global distribution in 34
countries. The Company is headquartered in San Diego, California and is the first to obtain FDA clearance and
CE Mark for a high-resolution PET scanner designed to image small body parts and for breast biopsy image
Executive Vice President
Naviscan Marketing Communications
321 Medical Launch